BeiGene, Ltd. (BGNE) has a consensus analyst rating of Buy, based on 18 analysts covering the stock. Of those, 13 recommend buying, 4 recommend holding, and 1 recommend selling.
The analyst consensus price target for BGNE is $258.00, representing a +39.7% upside from the current price of $184.71. Price targets range from a low of $205.00 to a high of $307.00.
